NEWS & BLOG
Stay up to date with the latest news and updates from KCNQ2 Cure.
KCNQ2-Related Epilepsy ICD-10 Codes Approved!
What is an ICD-10 Code? Developed by the World Health Organization (WHO), this is the tenth version of the International Classification of Diseases (ICD), known as ICD-10. It is a…
All that Jazz: Success of the 2024 New Horizons in Science Dinner
A night of jazz and jubilation in Melbourne at the fifth KCNQ2 Cure New Horizons in Science Dinner on April 11th. Volunteers decked out in New Orleans masks transformed host…
How my daughter’s medical history is a Tool Towards a CURE
My daughter Ella was only a month old when the neurologist at the third hospital she was sent to that month said, “Just go home and love her. We don’t…
KCNQ2 Cure and Invitae/Ciitizen partner on new observational study
The KCNQ2 Cure Alliance is excited to announce that we have partnered with Invitae Ciitizen to develop an Observational Study for patients affected by KCNQ2-DEE. Invitae Ciitizen has developed an…
KCNQ2-DEE Clinical Trial
Xenon Pharmaceuticals is currently developing XEN496, which is a proprietary pediatric formulation of the active ingredient ezogabine, for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE). Ezogabine was previously…
AES 2018
AMERICAN EPILEPSY SOCIETY 2018 and KCNQ2 The annual meeting of the American Epilepsy Society (AES) is the premier scientific meeting for the physicians, scientists, pharmaceutical industry, and patient groups engaged…
Old Friends, New Research, and How to See Around Corners
Old Friends, New Research, and How to See Around Corners Hi Everyone – Lots of exciting things are happening in the KCNQ2 community in cities and towns all over the…
- « Previous
- 1
- 2